Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
59
CME Quote, Financials, Valuation and Earnings
Last price:
$238.87
Seasonality move
:
4.21%
Day range:
$235.81 - $238.58
52-week range:
$190.70 - $249.02
Dividend yield:
4.14%
P/E ratio:
25.03x
P/S ratio:
14.17x
P/B ratio:
3.04x
Volume:
1.6M
Avg. volume:
2.4M
1-year change:
11.06%
Market cap:
$85.8B
Revenue:
$5.6B
EPS (TTM):
$9.51
Analysts' Opinion
-
Consensus RatingCME Group has received a consensus rating of . The company's average rating is a based on 5 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $242.38, CME Group has an estimated upside of 1.83% from its current price of $238.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $192.00 representing 100% downside risk from its current price of $238.01.
Fair Value
-
According to the consensus of 0 analysts, CME Group has 1.83% upside to fair value with a price target of $242.38 per share.
CME vs. S&P 500
-
Over the past 5 trading days, CME Group has underperformed the S&P 500 by -0.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CME Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CME Group has grown year-over-year revenues for 13 quarters straight. In the most recent quarter CME Group reported revenues of $1.6B.
Earnings Growth
-
CME Group has grown year-over-year earnings for 2 quarters straight. In the most recent quarter CME Group reported earnings per share of $2.50.
Enterprise value:
86.8B
EV / Invested capital:
2.74x
Price / LTM sales:
14.17x
EV / EBIT:
18.82x
EV / Revenue:
14.36x
PEG ratio (5yr expected):
1.86x
EV / Free cash flow:
23.91x
Price / Operating cash flow:
23.60x
Enterprise value / EBITDA:
17.53x
Gross Profit (TTM):
$5.2B
Return On Assets:
2.67%
Net Income Margin (TTM):
57.34%
Return On Equity:
12.57%
Return On Invested Capital:
11.18%
Operating Margin:
64.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5B | $5.3B | $6B | $1.3B | $1.6B | |
| Gross Profit | $4.2B | $4.5B | $5.2B | $1.1B | $1.4B | |
| Operating Income | $3B | $3.2B | $3.8B | $820.2M | $1B | |
| EBITDA | $4B | $4.5B | $5B | $1.1B | $1.3B | |
| Diluted EPS | $7.35 | $8.38 | $9.51 | $2.06 | $2.50 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $90.3B | $151.6B | $143.3B | $90.8B | $103.1B | |
| Total Assets | $125.8B | $186.8B | $178.4B | $125.6B | $137.8B | |
| Current Liabilities | $88.6B | $150.4B | $140.6B | $87.9B | $100.8B | |
| Total Liabilities | $98.7B | $159.5B | $150.2B | $97.4B | $109.6B | |
| Total Equity | $27B | $27.3B | $28.3B | $28.2B | $28.2B | |
| Total Debt | $3.4B | $3.4B | $3.4B | $3.4B | $3.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.7B | $3.4B | $3.7B | $856.7M | $1B | |
| Cash From Investing | -$396.5M | $15.6M | -$77.7M | -$19.5M | -$29.5M | |
| Cash From Financing | -$10.9B | -$56B | $8.6B | -$26.5B | $13.3B | |
| Free Cash Flow | $2.7B | $3.3B | $3.6B | $836.8M | $973.2M | |
CME
Sector
Market Cap
$85.8B
$694.8M
Price % of 52-Week High
95.58%
87.67%
Dividend Yield
4.14%
2.22%
Shareholder Yield
--
3.87%
1-Year Price Total Return
11.06%
7.29%
Beta (5-Year)
0.563
0.737
Dividend yield:
4.14%
Annualized payout:
$9.65
Payout ratio:
102.88%
Growth streak:
5 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$236.94
200-day SMA
Buy
Level
$214.07
Bollinger Bands (100)
Buy
Level
211.43 - 232.95
Chaikin Money Flow
Buy
Level
291.8M
20-day SMA
Buy
Level
$237.48
Relative Strength Index (RSI14)
Buy
Level
56.37
ADX Line
Sell
Level
10.72
Williams %R
Neutral
Level
-73.5963
50-day SMA
Buy
Level
$230.61
MACD (12, 26)
Buy
Level
2.12
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
350M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.6553)
Sell
CA Score
(Annual)
Level (-1.8091)
Buy
Beneish M-Score
(Annual)
Level (-2.2272)
Sell
Momentum Score
Level (6)
Buy
Ohlson Score
Level (0.3063)
Buy
Piotroski F Score
(Annual)
Level (8)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME’s acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Stock Forecast FAQ
In the current month, CME has received 5 Buy ratings 8 Hold ratings, and 0 Sell ratings. The CME average analyst price target in the past 3 months is $242.38.
-
Where Will CME Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that CME Group share price will rise to $242.38 per share over the next 12 months.
-
What Do Analysts Say About CME Group?
Analysts are divided on their view about CME Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CME Group is a Sell and believe this share price will drop from its current level to $192.00.
-
What Is CME Group's Price Target?
The price target for CME Group over the next 1-year time period is forecast to be $242.38 according to 0 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is CME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CME Group is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of CME?
You can purchase shares of CME Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CME Group shares.
-
What Is The CME Group Share Price Today?
CME Group was last trading at $238.87 per share. This represents the most recent stock quote for CME Group. Yesterday, CME Group closed at $238.01 per share.
-
How To Buy CME Group Stock Online?
In order to purchase CME Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
